Business
Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor. “After 27 years with Resmed, including 20 as CFO, Brett leaves an outstanding legacy of disciplined leadership and trusted partners
About this update from Resmed Inc.
[{"type":"image","alt":"Resmed, Inc.","displaySize":"","headline":null,"caption":"Resmed, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/730e54661ce751c82be107ad83b26aa1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5YVXbfS.5NH53XQ.naRljQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4/https://media.zenfs.com/en/globenewswire.com/730e54661ce751c82be107ad83b26aa1","width":300,"height":63}},"lazy":false},{"type":"text","content":"SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor.","length":368,"tagName":"p"},{"type":"text","content":"“After 27 years with Resmed, including 20 as CFO, Brett leaves an outstanding legacy of disciplined leadership and trusted partnership,” said Mick Farrell, Chairman and CEO of Resmed. “Brett’s leadership has helped guide Resmed through significant growth and transformation, while keeping a clear focus on long-term value creation and our goal to improve more than 500 million lives. On behalf of the Board and the entire Resmed team, I thank Brett for his exceptional contributions and wish him all the best in his well-earned retirement.”","length":540,"tagName":"p"},{"type":"text","content":"Aaron Bloomer joins Resmed from Exact Sciences, a global leader in cancer diagnostics recently acquired by Abbott, where he served as Chief Financial Officer.","length":158,"tagName":"p"},{"type":"text","content":"Aaron brings more than 17 years of global finance and operating leadership experience, with a strong track record of driving growth, operational discipline and shareholder value creation. At Exact Sciences, he helped shape and execute a new strategic plan that delivered strong revenue growth, significant margin expansion and substantial increases in free cash flow. Aaron also strengthened capital allocation frameworks and supported strategic M&A, as well as new product launches to expand the company’s portfolio.","length":521,"tagName":"p"},{"type":"text","content":"Previously, Aaron held senior finance leadership roles at...